Heated chemotherapy for bladder cancer that hasn't responded to BCG
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It's for people with a certain type of non-muscle-invasive bladder cancer that hasn't gotten better or has come back after BCG treatment, and who can't have or don't want bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of bladder cancer called high-grade non-muscle-invasive bladder cancer (including CIS) that was confirmed by biopsy.
- Your cancer did not respond to BCG treatment, or you couldn't tolerate BCG.
- You are not eligible for or have chosen not to have surgery to remove your bladder.
- Your doctor thinks heated chemotherapy (HIVEC) is a good option for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called HIVEC (a type of heated chemotherapy placed directly into the bladder) for people with non-muscle-invasive bladder cancer that is at medium or high risk of coming back. It aims to see if this approach can reduce the chance of cancer returning.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial studies adding “heat treatment” (hyperthermia) to standard bladder cancer care using radiation, sometimes with chemotherapy. It may help the radiation work better, but your eligibility depends on cancer stage, your general health, and certain heart and metal-safety issues.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.